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Introduction {#sec005}
============

The high burden of bloodstream infection (BSI) and increasing prevalence of BSI caused by antimicrobial-resistant (AMR) and multidrug-resistant (MDR) bacteria is a serious threat to global public health \[[@pone.0230501.ref001]--[@pone.0230501.ref006]\]. In Europe, BSIs caused by *Escherichia coli* resistant to third-generation cephalosporins (ESBL phenotype) have increased to a EU/EEA population-weighted mean percentage of 15% in 2017, whereas the corresponding mean for methicillin-resistant *Staphylococcus aureus* (MRSA) has decreased from 20% in 2014 to 17% in 2017 \[[@pone.0230501.ref007]\]. MRSA causes only 1.2% of all *S*. *aureus* BSIs in Sweden and has not increased significantly in the last 20 years. However, *E*. *coli* resistant to third-generation cephalosporins, usually producing extended-spectrum beta-lactamases (ESBL), increased from 5.6% in 2014 to 7.4% in 2017. Enterobacteriaceae resistant to fluoroquinolones followed by Enterobacteriaceae resistant to third-generation cephalosporins are probably the most frequently encountered and clinically important antimicrobial-resistant pathogens in Sweden today \[[@pone.0230501.ref008]--[@pone.0230501.ref010]\].

In septic shock, mortality risk increases if antibiotic treatment is delayed \[[@pone.0230501.ref011], [@pone.0230501.ref012]\]. Early appropriate empirical antibiotic treatment is therefore particularly important in septic shock, and must be initiated without delay before the results of blood cultures are available \[[@pone.0230501.ref013]--[@pone.0230501.ref016]\]. Since antimicrobial-resistant organisms have become more prevalent in most countries, the choice of appropriate antibiotics becomes increasingly challenging. Accordingly, up-to-date knowledge on the prevalence of microorganisms and their inherent/natural and acquired resistance to antimicrobial agents in serious infection is of major importance if we are to ensure appropriate empiric antimicrobial treatment \[[@pone.0230501.ref014], [@pone.0230501.ref017]--[@pone.0230501.ref019]\]. Furthermore, accurate estimations of AMR are necessary to establish the magnitude of the AMR problem on global, national, regional and local levels \[[@pone.0230501.ref020], [@pone.0230501.ref021]\]. Region Östergötland, with a catchment population of approximately 450,000 inhabitants (5% of the Swedish population), is served by four hospitals and has developed a database cross-linking systems providing microbiological data and mortality data from the patient care administration system. By analyzing data from this registry, we discovered a dramatic increase in community-onset BSI between 2000 and 2013 with comorbidity being the main risk factor for 30-day mortality associated with BSI \[[@pone.0230501.ref003]\]. The work presented here is a follow-up of a previous population-based study on BSI in the Region of Östergötland, aiming to investigate temporal trends in BSI more thoroughly, including distribution of species, AMR and risk factors for 30-day mortality associated with BSI.

Material and methods {#sec006}
====================

Design, setting and population {#sec007}
------------------------------

Setting: The study was carried out in a county in south-east Sweden served by four hospitals: a tertiary care university hospital (600 beds); two general hospitals (310 and 100 beds respectively); and one minor hospital (14 beds). The number of inhabitants in the county increased from approximately 423,000 to 452,000 over the study period, and currently represents approximately 5% of the Swedish population.

Study design: A retrospective cohort study on data from electronic records to describing and analyzing the incidence and 30-day all-cause mortality of culture-confirmed BSI in the Region of Östergötland, Sweden, between January 1, 2008 and December 31, 2016. Data were extracted from the Region Östergötland BSI registry as in a previous study performed in 2000--2013 \[[@pone.0230501.ref003]\].

Data collection {#sec008}
---------------

The following data were obtained from the Department of Clinical Microbiology in Region Östergötland: date of blood culture; number of aerobic and anaerobic blood culture vials taken; site of puncture; species identification; and susceptibility patterns. The dataset was entered into a secondary database where it was linked to the patient care administration system providing the following data for all patients with blood cultures taken: gender; age; comorbidity; admitting department; date of admission; date of discharge; and mortality. We restricted the dataset to a nine-year period from 2008 through 2016.

Microbiology {#sec009}
------------

All isolated microorganisms from outpatients care and hospital admissions were analyzed at the species level. Species identification and susceptibility testing were performed at the Region's Clinical Microbiology Department. Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) was used for microbial identification. Clinical susceptibility categories (susceptible, intermediate, and resistant) are defined by cut-offs or breakpoints for different antibiotics and bacteria using the disc diffusion method and Mueller-Hinton agar (MHA). For some bacteria complementary E-test was also applied. Antimicrobial susceptibility clinical breakpoints used during study period were classed as Susceptible (S), Intermediate (I) or Resistant (R) (European Committee on Antimicrobial Susceptibility Testing EUCAST). The intermediate (I) category was excluded from the resistance analyses based on the new definitions of (I) performed by EUCAST \[[@pone.0230501.ref022]\]. For surveillance purposes EUCAST advice against lumping categories and results should be recorded as S, I and R. If lumping does occur, EUCAST recommends to never lump I+R, only S+I. No major changes in cut-off values for resistance (R), that could have affected susceptibility testing results, were made during the study period.

Definitions {#sec010}
-----------

### Blood cultures {#sec011}

Blood cultures were taken on clinical indications. One set of blood cultures comprised one aerobic and one anaerobic blood culture bottle. It is recommended that at least two sets of blood cultures are taken simultaneously.

### Positive blood culture {#sec012}

Defined as the isolation of microorganisms (one or more bacterial or fungal isolates) from a set of blood cultures obtained on the same day in an adult (≥18 yrs). Only initial bacterial or yeast isolates were considered, thus repeat isolates of the same species with the same antibiogram (or change between S and I or I and R) from the same patient were excluded.

### Non-significant pathogens {#sec013}

Microorganisms typically belonging to the skin microbiota: (coagulase-negative *staphylococci*, (CoNS); *Micrococcus* spp.; *Bacillus* spp.; *Corynebacterium* spp.; and *Cutibacterium* spp.), were considered probable contaminants and excluded \[[@pone.0230501.ref023]\].

### Repeat isolate {#sec014}

Culture of same species with identical resistance pattern isolated during the same admission episode (from admission until hospital discharge). Repeat isolates were excluded.

### Multidrug resistance (MDR) {#sec015}

Non-susceptibility to at least 1 agent in ≥3 antimicrobial classes, ([S8 Table](#pone.0230501.s010){ref-type="supplementary-material"}) \[[@pone.0230501.ref024], [@pone.0230501.ref025]\].

### Antimicrobial resistance (AMR) {#sec016}

MDR bacteria and MRSA, ESBL-producing Enterobacteriaceae, vancomycin-resistant enterococci not fulfilling the MDR criteria were defined as antimicrobial-resistant (AMR) bacteria.

### BSI episode {#sec017}

An episode fulfilling the criterion "positive blood culture showing a significant pathogen". If a patient had more than one BSI episode per admission, only the first BSI episode was included in the analyses involving comorbidity and mortality.

### New BSI episode {#sec018}

Infection caused by a different bacterial or fungal pathogen \>3 calendar days after the previous BSI episode or by the same bacterial or fungal pathogen \>30 calendar days after the previous BSI episode.

### Defined-daily-dose (DDD) {#sec019}

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults according to WHO \[[@pone.0230501.ref026]\].

### Comorbidity {#sec020}

Comorbidity based on the International Classification of Diseases (ICD), ICD-10-CA and the updated Charlson Score Index \[[@pone.0230501.ref027]--[@pone.0230501.ref029]\] ([S11 Table](#pone.0230501.s013){ref-type="supplementary-material"}).

Antibiotic consumption {#sec021}
----------------------

All drug statistics were based on sale statistics measured as defined-daily-doses. Data were collected from national drug consumption statistics published by the Swedish e-Health Agency and accessed through a dedicated secure website \[[@pone.0230501.ref030]\]. Consumption of systemic antibiotics were analyzed both in outpatient care and hospital (defined either as J01 in the ATC-code for international comparison, or J01, excluding J01XX05 methenamine as the national Swedish quality indicator) was measured as defined-daily-doses (DDD) per 1,000 inhabitants and day. Use of systemic antibiotics in hospital was measured as DDD using hospital admission or hospital days as denominator \[[@pone.0230501.ref030], [@pone.0230501.ref031]\].

Statistical methods {#sec022}
-------------------

We assessed change in annual incidence of BSI using linear regression, presenting the change in incidence with a 95% confidence interval (CI). The predominant pathogens were defined at genus or species level, and annual trends were tested using linear regression. Chi-square and t-tests were used for univariate analyses to determine risk factors for 30-day all-cause mortality associated with BSI. Multivariable binomial regression analysis was used to calculate Incidence Rate Ratio and 95% confidence interval and to adjust for confounding factors. Patients with negative blood cultures were used as reference group. The following variables were used in the regression model and investigated as possible independent risk factors for mortality associated with BSI: gender; age; comorbidity; and year of diagnosis. The same variables plus BSI caused by AMR bacteria were investigated as risk factors for 30-day all-cause mortality. The annual antibiotic consumption was tested using linear regression. A p-value \< 0.05 was considered statistically significant. All statistical analyses were performed with Stata version 15.1.

Ethical approval {#sec023}
----------------

The Regional Ethics Review Board in Linköping, Sweden approved the study. Informed consent was not required. No details of the patients are disclosed and thus patient identity is secure. (Ref.no:2010/160-31).

Results {#sec024}
=======

Incidence of BSI, 30-day mortality and microorganisms {#sec025}
-----------------------------------------------------

A total of 9,268 BSIs fulfilling the inclusion criteria were recorded between January 2008 and December 2016 and subsequently analyzed ([Fig 1](#pone.0230501.g001){ref-type="fig"}). 46% (n = 4,242) of the BSI-episodes represented by patients were female and the median age of all patients with a positive blood culture increased from 69 to 70 years (p = 0.01). The most common agents causing BSI were Gram-negative bacteria (50%), Gram-positive bacteria (38%) other bacteria (8%) and *Candida* spp. (4%). The incidence of BSI increased by 66% from 973 in 2008 to 1,610 in 2016 per 100,000 hospital admissions with an average annual increase of 78 BSI episodes per 100,000 hospital admissions during the study period (p\<0.01) ([S1 Fig](#pone.0230501.s001){ref-type="supplementary-material"}, [S2 Table](#pone.0230501.s004){ref-type="supplementary-material"} and [S3 Table](#pone.0230501.s005){ref-type="supplementary-material"}). However, the incidence reached a plateau in 2013.The 30-day all-cause mortality rate amongst patients with BSI increased from 162 per 100,000 hospital admissions per year in 2008 to 189 in 2016; an increase of 17% (p\<0.01). Over the study period, a total of 1,237 patients died within 30 days after the date when blood cultures were obtained, giving an overall 30-day mortality of 13%. The 30-day all-cause mortality of patients with BSI and two or more comorbidities increased by 98% (p\<0.01) ([S2 Fig](#pone.0230501.s004){ref-type="supplementary-material"} and [S9 Table](#pone.0230501.s011){ref-type="supplementary-material"}).

![Flow-chart---study-design.\
\*Microorganisms typically belonging to the skin microbiota: (coagulase-negative *staphylococci*, (CoNS); *Micrococcus* spp.; *Bacillus* spp.; *Corynebacterium* spp.; and *Cutibacterium* spp.), were considered probable contaminants and excluded \*\*Culture of same species with identical resistance pattern isolated during the same admission episode (from admission until hospital discharge) was excluded. \*\*\*9,268 Episodes of BSIs consisted of 8,498 patients (patient with ≥3 BSI-episodes/year = n142, 2 = n317, 1 = n311). \*\*\*\*Total of 9,587 microorganism were analyzed based on BSI-episodes (included polybacterial isolates (n255) and repeat isolate that is not excluded by the definition "repeat isolate" and not cause a new BSI episode (n64).](pone.0230501.g001){#pone.0230501.g001}

In all, 9,587 microorganisms were isolated from blood cultures. *Escherichia coli* was the most frequently found cause of BSI, increasing by 93% from 192 to 390 BSIs per 100,000 hospital admissions (p\<0.01), with a 30-day all-cause mortality of 8.7%. The second most frequent cause of BSI was, *Staphylococcus aureus* increasing by 55% from 145 to 236 BSIs per 100,000 hospital admissions (p = 0.03) with a 30-day all-cause mortality of 19%. Another species that increased significantly was *Proteus mirabilis* with a 177% increase from 9 to 26 BSIs per 100,000 hospital admissions (p\<0.01), and a 30-day all-cause mortality of 13%. Among fungi, a significant increase in *Candida albicans* was recorded, rising by 269% from 11 to 43 BSIs per 100,000 hospital admissions (p = 0.01), with a 30-day all-cause mortality of 29% ([S1 Table](#pone.0230501.s003){ref-type="supplementary-material"} and [S2 Table](#pone.0230501.s004){ref-type="supplementary-material"}).

The overall proportion of hospital admissions in which a blood culture was obtained increased from 11 to 19% (p\<0.01). The proportion of hospital admissions during which a positive blood culture was found increased from 1.1 to 1.8% (p\<0.01), though there was a minor decrease in the proportion of blood cultures that were positive per total number of blood cultures (from 10 to 9%, (p = 0.11)) ([S3 Table](#pone.0230501.s005){ref-type="supplementary-material"}). Annual distribution of species and associated 30-day mortalities are shown in [S2 Table](#pone.0230501.s004){ref-type="supplementary-material"} and [S4 Table](#pone.0230501.s006){ref-type="supplementary-material"}.

Consumption of antimicrobial agents {#sec026}
-----------------------------------

During the study period, antibiotics for systemic use dispensed to outpatients decreased by 13% from 11.75 to 10.22 (DDD per 1,000 inhabitants and day (TIND)) (p\<0.01) and increased by 17% from 1.28 to 1.50 in hospital wards and polyclinics (DDD/TIND) (p\<0.01). The total amount of systemic antibiotics (J01) used in hospital increased by 48% (from 524 to 777 DDD per 1,000 hospital days (2008--2016)) (p\<0.01). This corresponds to an increase in DDD per hospital admission of 18% from 2.86 to 3.38. (p = 0.01).When analyzed at the 5^th^ ATC level as defined by WHO, different groups of systemic antibiotics used in hospital increased as follows: penicillin combinations including beta-lactamase inhibitors, (J01CR) increased by 224% from 26.4 to 85.5 DDD per 1,000 hospital days (p\<0.01); carbapenems (J01DH) increased 53%, 31.3 to 48.0 (DDD per 1,000 hospital days) (p\<0.01); beta-lactamase-sensitive penicillins (J01CE) 79%, 41.1 to 73.5 (DDD per 1,000 hospital days) (p\<0.01); beta-lactamase-resistant penicillins (J01CF) increased by 109% from 65.8 to 137.8 (DDD per 1,000 hospital days) (p\<0.01); penicillins with extended spectrum (J01CA) 48%, 50.3 to 74.4 (DDD per 1,000 hospital days) (p\<0.01); and cephalosporins (J01 DB-DE) increased by 24% from 81.2 to 100.9 DDD per 1,000 hospital days (p\<0.01) ([S5 Table](#pone.0230501.s007){ref-type="supplementary-material"}, [S6 Table](#pone.0230501.s008){ref-type="supplementary-material"} and [S7 Table](#pone.0230501.s009){ref-type="supplementary-material"}).

Antimicrobial resistance {#sec027}
------------------------

Increased resistance to antimicrobial agents was observed during the study period. During the study period we observed significant increases in fluoroquinolone-resistance (3.7 to 7.7% (p = 0.01) and cephalosporin-resistance (2.5 to 5.2% (p = 0.03) amongst Enterobacteriaceae ([S10 Table](#pone.0230501.s012){ref-type="supplementary-material"}). Theresistance of *E*.*coli* to ciprofloxacin increased from 9 BSI episodes to 43 (6.7--11%), 2008--2016 (p = 0.02). Furthermore, *E*. *coli* resistance to tobramycin increased from 2 to 19 (1.0--4.9%) (p = 0.03). Significantly increased piperacillin-tazobactam resistance rates were observed among several Gram-negative bacteria; *Pseudomonas aeruginosa* 0 to 5 (0--19.2%), *Klebsiella oxytoca* 0--3 (0--13%), and *Enterobacter cloacae* 0--6 (0--17.1%) (\<0.01). Furthermore, there was an increase in resistance to trimethoprim-sulfamethoxazole 1--7 (11.1--26.9%), (p = 0.03) and ciprofloxacin 0--1 (0--3.8%), (p = 0.03) amongst isolates of *Proteus mirabilis* ([S4 Table](#pone.0230501.s006){ref-type="supplementary-material"}).

Antimicrobial resistance and 30-day all-cause mortality {#sec028}
-------------------------------------------------------

A total of 245 AMR BSIs (2.6%) were observed and among those 185 were caused by MDR bacteria; ESBL *E*. *coli* (ESBL-E) (n = 74), ESBL *Klebsiella pneumoniae* (ESBL-K) (n = 22), MRSA (n = 6), non-ESBL *E*. *coli* (n = 62), others (n = 38) and non-MDR bacteria (n = 60); (ESBL-E (n = 48), ESBL-K (n = 3), MRSA (n = 7) and VRE (n = 2)). AMR BSIs increased by 300%, from 12 to 47 per 100,000 hospital admissions, 2008--2016 (p = 0.01) ([Fig 2](#pone.0230501.g002){ref-type="fig"} and [Table 1](#pone.0230501.t001){ref-type="table"}). The 30-day all-cause mortality due to BSIs caused by AMR BSI was 9.4%, ESBL-E 6.8%, MDR *E*. *coli* 4.8% which was lower than the 8.7% 30-day all-cause mortality rate for all *E*. *coli* BSIs [Table 2](#pone.0230501.t002){ref-type="table"}.

![AMR BSIs per 100,000 hospital admissions and year, 2008--2016.\
Incidence of AMR BSI increased by 300% from 12 to 47 per 100,000 hospital admissions, 2008--2016, (Linear regression) (p = 0.01).](pone.0230501.g002){#pone.0230501.g002}

10.1371/journal.pone.0230501.t001

###### Distribution of antimicrobial resistant (AMR) bacteria per 100,000 hospital admissions.

![](pone.0230501.t001){#pone.0230501.t001g}

                                                                                                               Regression per 100,000 hospital admissions[\*\*](#t001fn002){ref-type="table-fn"}   30-day mortality                         
  ---------------------- ---------------------------- ---- ---- ---- ---- ---- ---- ---- ---- ----- ------ --- ----------------------------------------------------------------------------------- ------------------ --------- ----------- -----------
  **AMR BSI**            8                            29   13   19   30   28   36   48   34   245   305%   5   1.53--8.04                                                                          0.01               23 (9%)   222 (91%)   
  **MDR-bacteria**                                    3    20   10   18   26   23   23   34   28    185    .   4                                                                                   1.62--6.11         \<0.01    17 (9%)     168 (91%)
                         Escherichia coli             2    6    4    5    9    9    6    11   10    62     .   1                                                                                   0.49--1.66         \<0.01    3 (5%)      59 (95%)
                         ESBL *E*.*coli*              0    7    3    4    9    9    11   18   13    74     .   2                                                                                   1.22--3.56         \<0.01    5 (7%)      69 (93%)
                         ESBL *Klebsiella spp*        0    2    3    5    7    1    3    0    1     22     .   0                                                                                   -1.16--0.87        0.75      5 (23%)     17 (77%)
                         MRSA                         1    2    0    1    0    0    2    0    0     6      .   0                                                                                   -0.52--0.19        0.30      2 (33%)     4 (67%)
                         *Acinetobacter baumannii*    0    0    0    0    0    1    1    0    1     3      .   0                                                                                   -0.01--0.33        0.06      1 (33%)     2 (67%)
                         *Pseudomonas aeruginosa*     0    0    0    1    0    0    0    0    0     1      .   0                                                                                   -0.17--0.12        0.73      0           1 (100%)
                         *Proteus mirabilis*          0    0    0    0    0    0    0    1    0     1      .   0                                                                                   -0.07--0.20        0.27      0           1 (100%)
                         *Staphylococcus aureus*      0    2    0    0    0    1    0    0    1     4      .   0                                                                                   -0.35--0.30        0.86      0           4 (100%
                         *Streptococcus pneumoniae*   0    1    0    2    1    2    0    4    2     12     .   0                                                                                   -0.01--0.90        0.10      1 (8%)      11 (92%)
  **Non-MDR bacteria**                                5    9    3    1    4    5    13   14   6     60     .   1                                                                                   -0.84--2.69        0.26      6 (10%)     54 (90%)
                         ESBL *E*.*coli*              4    8    2    1    3    3    11   13   3     48     .   1                                                                                   -1.13--2.45        0.41      2 (4%)      46 (96%)
                         ESBL *Klebsiella spp*        0    1    0    0    0    2    0    0    0     3      .   0                                                                                   -0.33--0.28        0.86      2 (67%)     1 (33%)
                         MRSA                         1    0    1    0    0    0    2    0    3     7      .   0                                                                                   -0.22--0.66        0.28      2 (29%)     5 (71%)
                         VRE                          0    0    0    0    1    0    0    1    0     2      .   0                                                                                   -0.12--0.25        0.41      0           2 (100%)

\* Change in rate from 2008--2016 per 100,000 hospital admissions.

\*\*Average annual increase (AAI). Increased microorganism per year per 100,000 hospital admissions (average annual increase), Linear regression.

10.1371/journal.pone.0230501.t002

###### Characteristics of all BSIs, AMR BSIs, susceptible *E*. *coli* BSIs, ESBL *E*.*coli* and MDR *E*. *coli BSIs*.

![](pone.0230501.t002){#pone.0230501.t002g}

                        All BSIs    AMR BSIs    Susceptible *E*.*coli*   ESBL *E*.*coli*   MDR *E*.*coli*
  --------------------- ----------- ----------- ------------------------ ----------------- ----------------
  **All**               **9268**    **245**     **3143**                 **122**           **62**
  Male n (%)            5005 (54)   78 (62)     1446 (46)                79 (64)           50 (63)
  Mean Age (SD)         70 (17)     67 (17)     72 (16)                  64 (19)           66 (18)
  Charlson Index (SD)   2.5 (2.7)   1.8 (2.5)   2.2 (2.3)                1.7 (2.8)         1.7 (2.4)
  Mortality (%)         13          9.4         8.7                      6.8               4.8

Univariate and multivariable risk factor analyses {#sec029}
-------------------------------------------------

Age, gender, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, connective tissue disease (rheumatic disease), renal disease and cancer were significantly associated with 30-day all-cause mortality in univariate analyses. Non-survivors (30-day all-cause mortality due to BSI) had a significantly higher mean Charlson comorbidity score (mean = 3.81, SD = 3.72--3.90 compared to survivors (mean 1.79 (1.73--1.85), p\<0.01) [Table 3](#pone.0230501.t003){ref-type="table"}.

10.1371/journal.pone.0230501.t003

###### Baseline characteristics and comparison of patients according to 30-day all-cause mortality.

![](pone.0230501.t003){#pone.0230501.t003g}

                                                                                 Non-survivors       Survivors                                       
  -------------------------------- --------------------------------------------- ------------------- ----------------------------------------------- ---------------------------------------------
  **Demographics**                                                                                                                                   
                                   **Male**                                      692 (56)            4334 (54)                                       0.19
                                   Mean age± (SD)                                76±12.8             69±18.6                                         0.01[\*\*](#t003fn002){ref-type="table-fn"}
                                   \>65 years                                    79                  77                                              
  **Comorbidity**                                                                                                                                    
                                   Myocardial infarction                         223 (18)            1044 (13)                                       \<0.01
                                   Congestive heart failure                      383 (31)            1526 (19)                                       \<0.01
                                   Peripheral vascular disease                   111 (9.0)           484 (6.0)                                       \<0.01
                                   Cerebrovascular disease                       210 (17)            1044 (13)                                       \<0.01
                                   Dementia                                      73 (5.9)            322 (4.0)                                       0.01
                                   Chronic pulmonary disease                     198 (16)            1124 (14)                                       0.12
                                   Connective Tissue Disease-Rheumatic Disease   99 (8.0)            482 (6.0)                                       0.03
                                   Peptic ulcer disease                          49 (4.0)            242 (3.0)                                       0.14
                                   Mild liver disease                            50 (4.0)            401 (5.0)                                       0.89
                                   Diabetes without chronic complications        309 (25)            1767 (22)                                       0.05
                                   Diabetes with chronic complications           76 (6.1)            403 (5.0)                                       0.21
                                   Paraplegia and hemiplegia                     72 (5.8)            482 (6.0)                                       0.99
                                   Renal disease                                 210 (17)            884 (11)                                        \<0.01
                                   Cancer                                        445 (36)            2010 (25)                                       \<0.01
                                   Moderate or severe liver disease              61 (4.9)            162 (2.0)                                       \<0.01
                                   Metastatic carcinoma                          173 (14)            643 (8.0)                                       \<0.01
                                   HIV/AIDS                                      0 (0)               7 (0.1)                                         0.99
  **Number of comorbidities**                                                                                                                        
                                   0                                             147 (12)            2425 (30)                                       \<0.01
                                   1                                             307 (25)            2101 (26)                                       0.36
                                   2                                             302 (24)            1453 (18)                                       \<0.00
                                   \>2                                           481 (39)            2021 (25)                                       \<0.01
  **Charlson comorbidity score**   3.81 (3.72--3.90)                             1.79 (1.73--1.85)   \<0.01[\*\*](#t003fn002){ref-type="table-fn"}   

\*Chi^2^-analysis

\*\* Student-T-test

Multivariable analyses showed the following to be risk factors for 30-day mortality: age (RR 1.02 (95% CI: 1.02--1.03); one comorbidity RR 2.06 (95% CI: 1.60--2.52); two comorbidities RR 2.79 (95% CI: 2.27--3.42); and three or more comorbidities RR 2.82 (95% CI: 2.31--3.45). Patients with an AMR BSI had a significantly lower 30-day all-cause mortality; RR 0.89 (95% CI: 0.81--0.97) p = 0.01 [Table 4](#pone.0230501.t004){ref-type="table"}.

10.1371/journal.pone.0230501.t004

###### Multivariable analyses--factors for 30-day all-cause mortality in BSI.

![](pone.0230501.t004){#pone.0230501.t004g}

                                                   BSI Incidence   30-day mortality                                  
  ------------------------------------------------ --------------- ------------------ -------- ------ -------------- --------
  Age                                              1.01            (1.01--1.01)       \<0.01   1.02   (1.02--1.03)   \<0.01
  Male                                             0.99            (0.95--1.03)       0.58     1.05   (0.94--1.17)   0.39
  **Number of comorbidities**                                                                                        
  0                                                1                                           1                     
  1                                                1.25            (1.18--1.32)       \<0.01   2.06   (1.68--2.52)   \<0.01
  2                                                1.32            (1.24--140)        \<0.01   2.79   (2.27--3.42)   \<0.01
  ≥3                                               1.58            (1.50--1.67)       \<0.01   2.82   (2.31--3.45)   \<0.01
  AMR BSI[\*\*](#t004fn002){ref-type="table-fn"}                                               0.89   (0.81--0.97)   0.01

\* Multivariate binomial regression analysis

\*\* MDR bacteria and MRSA, ESBL, VRE)

Discussion {#sec030}
==========

In this study BSI incidence, 30-day all-cause mortality and AMR-bacteria increased over the study period. Surprisingly, the study showed lower 30-day all-cause mortality among patients with BSI caused by AMR bacteria including ESBL, MRSA and VRE without MDR, compared to those with susceptible bacteria. The dominant risk factor for 30-day all-cause mortality associated with BSI was comorbidity, which agrees with previous studies \[[@pone.0230501.ref003], [@pone.0230501.ref032], [@pone.0230501.ref033]\]. The incidence of BSI and associated 30-day all-cause mortality per 100,000 hospital admissions increased over the study period by 66%, and 17% respectively which is consistent with the results of other studies \[[@pone.0230501.ref004], [@pone.0230501.ref034], [@pone.0230501.ref035]\]. The incidence of BSI and the 30-day all-cause mortality reached a plateau in 2013 and thereafter mortality decreased between 2013 and 2016. Other studies have reported a stable or even decreased incidence of BSI and associated mortality \[[@pone.0230501.ref036], [@pone.0230501.ref037]\]. The overall 30-day all-cause mortality among patients with BSI was 13%, which is similar to that estimated in Europe and North America, and also seen in Finland \[[@pone.0230501.ref002], [@pone.0230501.ref004]\]. There are several factors that could explain the increase in the annual incidence of BSI up to 2013, including the increase in the number of blood cultures taken per hospital admission; a direct result of increased compliance with the principle of taking blood cultures before starting antibiotic treatment. However, the proportion of positive blood cultures did not change significantly over the study period. If potential areas for improvement are to be found, other possible explanations for the observed increase in BSI must be studied, both in previously healthy patients and those with comorbidities.

In the present study, *E*. *coli* was the most common cause of bloodstream infection; the incidence increasing by almost 100% between 2008 and 2016. We also found an increase in BSI caused by *E*. *coli* resistant to quinolones, cephalosporins and aminoglycosides, which concurs with global trends \[[@pone.0230501.ref034], [@pone.0230501.ref037]--[@pone.0230501.ref040]\]. BSI caused by ESBL-producing Enterobacteriaceae increased during the study period, though the rate was low compared to many other European countries; the numbers, however, are increasing \[[@pone.0230501.ref007]\]. The reason for the rapid dissemination of ESBL-producing Enterobacteriaceae is likely multifactorial with travel and migration as driving forces \[[@pone.0230501.ref041], [@pone.0230501.ref042]\].

Antibiotic hospital consumption increased by approximately 50% measured as DDD per 1,000 hospital days (p\<0.01) comprising both narrow- and broad-spectrum drugs ([S6 Table](#pone.0230501.s008){ref-type="supplementary-material"}). Several factors could explain this. First of all, BSIs per 100,000 hospital days increased by 108% ([S3 Table](#pone.0230501.s005){ref-type="supplementary-material"}) and per 100,000 hospital admissions by 66%; hence the increased use of antibiotics in hospitals. Second, the number of patients with multiple comorbidities increased, and since these patients are at greater risk for severe illness they were probably prescribed more antibiotics \[[@pone.0230501.ref043]\]. Third, modern guidelines recommend higher and more frequent doses of antibiotics which would naturally lead to increased consumption as measured by DDD based on standard doses for the main indication \[[@pone.0230501.ref044]--[@pone.0230501.ref049]\]. This study was not designed to see if the decrease in antibiotic treatment in outpatients correlated with the increase in antibiotic use in hospital, since we did not consider antibiotic use in individual patients.

Similar to trends in the other Nordic countries, the use of piperacillin-tazobactam (PTZ) and amoxicillin-clavulanic acid increased rapidly \[[@pone.0230501.ref050]\]. It is interesting to note a concurrent increase in PTZ resistance among *Klebsiella oxytoca* and *Enterobacter cloacae* as well as *Pseudomonas aeruginosa*, but the study was not designed to show causal relationship between consumption and emergence of resistance to PTZ. In other studies, however, degree of exposure to PTZ has paralleled the emergence of PTZ resistance among *P*. *aeruginosa* when cephalosporins have been replaced by PTZ \[[@pone.0230501.ref051]\]. This warrants further investigation since *P*. *aeruginosa* can cause healthcare-associated infections that are difficult to treat.

Only 2.6% of all BSIs were caused by AMR bacteria. The restricted use of systemic antibiotics in the Swedish primary healthcare system and in animals, probably explains why we have a relatively low prevalence of AMR bacteria compared to other European countries. In the hospital setting however, antibiotic consumption is similar to other European countries \[[@pone.0230501.ref052], [@pone.0230501.ref053]\]. Other concomitant factors that could explain the low level of AMR rates in Sweden include a high degree of food safety, improved hygiene and infection prevention measures, and meticulous sanitation. In the design of this study we decided to use the generally accepted definition of multidrug resistance (MDR) *i*.*e*. non-susceptibility to at least 1 agent in ≥3 antimicrobial classes \[[@pone.0230501.ref024], [@pone.0230501.ref025]\]. However, application of this MDR definition to our data would exclude a significant number of MRSA, ESBL-producing Enterobacteriaceae not fulfilling the MDR criteria thereby underestimating the frequency of AMR. Thus, we report MDR but also AMR without multidrug resistance (MRSA, ESBL-producing Enterobacteriaceae, vancomycin-resistant enterococci not fulfilling the MDR criteria.

Surprisingly, multivariable analyses showed a lower 30-day all-cause mortality among patients with BSI caused by AMR bacteria including ESBL, MRSA and VRE without MDR, compared to those with susceptible bacteria \[[@pone.0230501.ref054]\], while other studies have reported the opposite \[[@pone.0230501.ref032], [@pone.0230501.ref055], [@pone.0230501.ref056]\]. Further studies are needed to explain the lower mortality rate found in this group. In the present study, patients with a BSI caused by AMR bacteria were younger and had less comorbidity. It is possible that people of this age are more exposed to AMR-bacteria because of frequent travel. Furthermore, patients with AMR BSI may receive longer intravenous antibiotic therapy and spend more time in hospital as well, thereby may reducing the chance of recurrent infection. A current lack of resources obliges us to reduce in-hospital times with the result that patients with sensitive bacteria might discharged prematurely. In Sweden, patients with AMR bacteria are usually treated by an infectious disease specialist. Infectious disease consultation has been shown to improve outcome in S. aureus sepsis \[[@pone.0230501.ref057]\] and this may also have influenced the treatment of BSI caused by AMR bacteria of other species including ESBL-E. coli which was the most prevalent AMR bacteria found in this study. Improved care due to involvement of an ID specialist may be an explanation for the better outcome and lower mortality rate among patients with AMR bacteria. \[[@pone.0230501.ref054], [@pone.0230501.ref058]--[@pone.0230501.ref060]\]. This warrants further study and we are planning a case-control study with extensive data on patients and bacteria, including virulence factors, in order to gain a better insight into why patients with ESBL-E. coli BSI have a better outcome in our setting.

A limitation of this study was that we did not divide the cohort into community-acquired and hospital-acquired infections due to the difficulty in defining these groups. Another limitation was that risk factor and mortality analysis was performed on the first BSI even if a patient admitted for a community-acquired BSI suffered a hospital-acquired BSI during the same admission. However, since only 2% of patients had more than one BSI during the same admission, this limitation could only have a minor influence on the results. Furthermore, CoNS was considered a contaminant, thus excluding central line-associated BSIs (CLABSI) caused by CoNS; the reason being that these analyses are complicated, and our aim was to simplify things by using a bacteremia database as a tool in our effort to improve the management of BSI. A major limitation is that individual patient data on severity of disease, site of infection and appropriate antibiotic treatment were not available in our database; we were thus unable to assess any association between antibiotic use and risk for antibiotic-resistant infection, or between specific empirical regimens and outcome. Nor could we determine if delay in appropriate antibiotic treatment was a risk factor for mortality as shown by Andersson et al \[[@pone.0230501.ref012]\] in a similar setting. Furthermore, other causes of mortality such as myocardial infarction, pulmonary embolus or respiratory failure were only registered as comorbidity and not evaluated as a primary cause of death. Since this was mainly an explorative analysis, we have not adjusted the p-values; a measure usually taken when testing multiple hypotheses.

Conclusion {#sec031}
==========

Comorbidity was the predominant risk factor for 30-day all-cause mortality associated with BSI in this study. The burden of AMR was low and not associated with increased mortality. Patients with BSIs caused by AMR bacteria (MDR, MRSA, ESBL and VRE) were younger, had fewer comorbidities, and the 30-day all-cause mortality was lower in this group. The reason for this will be the subject of further studies.
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Reviewer \#3: Yes
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?
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Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

Reviewer \#5: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: General comment

This is a retrospective cohort study analysing blood culture isolates form a Swedish county, covering the years 2008-2016. The authors demonstrate that BSI have been increasing over time, that BSI caused by resistant pathogens are rare in this specific setting and that 30-day mortality is mainly related to the patient comorbidities. The main limitation is the lack of important confounder variables in the mortality analysis (e.g. appropriate antibiotic treatment, site of infection, severity of illness). The discussion needs restructuring.

Detailed comments

Introduction

\- line 78: Write out BSI when first mentioning

Methods

\- line 118: are isolates from outpatients outside the four hospitals also represented in the database?

\- line 195: you are performing dozens of statistical tests in your analysis. Consider adjusting the p-values for multiple testing, or mention this as a limitation.

Results

\- line 219: 9268 BSI from how many patients?

\- line 231: regarding increased 30d mortality over time: Could it be that follow-up was different over time? In other words, how sure can you be about those patients for whom no death was reported? Please comment.

\- line 254: what is the difference between the 17% increase mentioned on line 253 and the 48% on line 254?

\- line 256: what does "analysed at the 5th ATC level" mean?

\- Table 1: Comment: From an epidemiological perspective, separation between MDR and non-MDR ESBL does not make much sense.

\- Table 3: p-value for gender is missing

\- Table 4: a limitation of your analysis is the small number of potential confounders. What about severity of disease? Site of infection? Lower mortality with AMR is strange and is probably a result of residual confounding.

Discussion

\- Paragraph 1 is not well structured. You are intermingling all aspects of your results in the first paragraph, which is puzzling to the reader. This should be a summary of your main findings. In general, do not repeat details of your results in the discussion and do not refer to Tables if not necessary.

\- line 361: I am not sure. At the same time guidelines recommend shorter courses of antibiotic treatment for many indications compared to 10 years ago. If you stick to this argument, please give a reference.

Reviewer \#2: Methods

1\. Were all BSIs diagnosed in-hospital or in the community as well? Please specify

2\. What methods do you use for pathogen identification and antimicrobial susceptibility?

3\. You defined that the intermediate (I) category was excluded from the resistance analyses. If the numbers are small it may be negligible, but consider adding it to the resistant (R) category.

4\. In analyses involving mortality only the first BSI per admission was included. How many patients had recurrent admissions with BSIs? If a significant amount then that introduces bias.

5\. From the results I understand that antibiotic consumption data was based on dispensing. Please specify in methods.

Results

1\. Add the excluded BSIs and reasons for exclusion.

2\. Data are lacking regarding source of infection, place of acquisition, number of patients (not only number of BSIs)- if available please add

3\. Antimicrobial resistance- instead of stressing specific bacteria, e.g. Klebsiella oxytoca resistant to PTZ (only 0-3 cases), I would specify general data- quinolone-resistant Enterobacteriaceae, PTZ-resistant Enterobacteriaceae, etc.

4\. Table 2- I would change \"univariate analysis\" to \"characteristics\"

5\. Table 3- specifying male and female both is redundant, there are no units for some of the categories (\>65- %, charlson score- maybe median (IQR)), for mean (age) add SD.

6\. Table 4- this is the only place that refers to the multivariate analysis for BSI incidence. There is no reference to these results in the text. Also this means that data on patients without BSI had to be extracted and if so, however there is no mention of these patients?

Discussion

1\. The result that AMR BSI confers protection against mortality is, as mentioned, very surprising. Explaining this by the observation that they were younger and had less comorbidity is not enough as this is surprising as well. Also, I don't understand the claim that they were less subject to treatment limitation

Grammar

1\. Line 89- pathogens instead of agents

2\. Line 126- in 2000-2013

Reviewer \#3: I don\'t have many comments. I think this was a good piece of research, well-written with appropriate statistics. My only suggestions is that the Definitions section should come in an appendix rather than in the middle of the manuscript and the thought that the reason that the mortality burden of AMR was low was perhaps due to the restricted use of antibiotics in primary care in Sweden. The authors may want to suggest this.

Reviewer \#4: The authors performed a nine-year observational retrospective study aimed at describing the epidemiology of BSIs in a county in South-East Sweden. Data on BSI episodes were gathered from the microbiology laboratory database and linked to electronic health records available for the same hospitalization. At the same time the authors describe the trend of antimicrobial consumption in the same hospitals by analyzing DDDs/patient days and consumption in the outpatient setting by analyzing DDs/inhabitants.

The study shows a rising trend in the incidence of BSIs and also a rising 30-day mortality rate in patients diagnosed with bacteremia. In-hospital antimicrobial consumption is also increasing, probably as the consequence of the increasing age and comorbidities of admitted patients. The authors already published part of this dataset, showing the relationship between comorbidities and mortality in bacteremic patients. In this new study, they analyzed a larger cohort adding data on antimicrobial resistance and antimicrobial consumption.

My main concern with this study is the unclear study design. When dealing with large databases, it is very common to find significant results and infer causal relationship from these results. However, this approach should generally be avoided if there is no a pre-defined/biologically plausible hypothesis grounding the analysis. In this case, for example, the authors found a significant association between comorbidities and 30-day mortality, proving a biologically plausible hypothesis (already present in previous results from the same cohort). However, when coming to AMR, the analysis shows that AMR has a significant protective effect, even after correcting with comorbidities and age. Unfortunately, with the available data this cannot be explained and proves the difficulty of dealing with this type of data. When testing risk factors for mortality in BSIs we should probably not accept analyses that cannot include relevant patient-level data, such as antibiotic therapy and appropriate measures of infection severity.

Few other comment on the text follows:

Abstract: the study-design should be mentioned in the abstract and in the methods it should be clearly stated how the data collection was performed and how the study was planned (retrospective cohort from electronic records..).

AMR/MDR definition: definition used is quite tricky because MRSA should be always considered MDR. It is difficult to imagine that approximately 1/3 of ESBLs are resistant to less than 3 classes (so not falling under the MDR definition). I would suggest reconsidering this categorization dividing pathogens according to their phenotypic resistance, rather than number of classes (FQ-R E. coli; ESBL-Ent; MRSA, VRE...).

Discussion:

-Increasing incidence and blood cultures: in the discussion the authors state that the increase number of BSIs is probably not due to the growing number of patients tested because the proportion of positive blood cultures remain the same. I would advise to report somewhere the overall number of blood cultures performed, rather than the proportion to better exclude this confounder.

-Line 379: association between AMR and antimicrobial consumption, sanitation, food safety is a very complex issue. I would advise rephrasing as '...these are all concomitant factors that could explain the low level of AMR rates in Sweden'.

-Line 386: what do the author mean with treatment limitation? The association with AMR remains significant even if adjusting per age and comorbidities, so they probably should not be considered as relevant factors.

Reviewer \#5: This study investigated the risk factors for 30-day mortality among hospitalized bacteraemia patients in a county in Sweden over a nine-year period, using routinely-collected linked data and taking into consideration antibiotic susceptibility. Overall, I read this article with interest and appreciate how much work the authors have done and how much data they have provided. I do, however, think amendments and additional clarification need to be provided before this article can be considered for publication.

Main amendments:

Line 147 -- Why were the intermediate isolates excluded? In many other studies "intermediate" and "resistant" have been combined to the category of "non-susceptible" and compared with "susceptible". It could be a useful sensitivity analysis to investigate whether including these isolates in the "non-susceptible" category alters the results significantly. Alternatively, quantifying how many intermediate isolates were excluded and what the rationale behind this decision was would be helpful.

Lines 159-161 and lines 166-168 -- How did the authors handle non-identical antibiograms? Was the most resistant antibiogram chosen (standard practice)? What about polymicrobial blood cultures?

Lines 171-173 -- Why was AMR not simply defined as any culture resistant to any of the antibiotics included in the standard panel? Using the definition outlined by the authors, were some antibiotic-resistance profiles missed?

Lines 174-179 -- How was the new BSI episode definition devised (references, expert opinion etc.)? What is the rationale behind only using the first BSI episode within a hospitalization? I would imagine that patients with more than one BSI episode (defined as being caused by different aetiogical agents) would be at a higher risk of dying within 30 days?

Lines 182-183 -- Outlining the conditions that make up the Charlson Comorbidity Index would be useful, as well as how the Index is calculated and whether the CCI was the only measure of comorbidity used or whether comorbidities were looked at separately.

Definitions -- Please outline whether mortality was 30-day all-cause mortality following a BSI episode and/or how mortality was attributed to the BSI. If the measure was 30-day all-cause mortality following a BSI, please update the wording of this throughout the manuscript.

Lines 234-242 -- It would possibly be more informative to report on the relative proportions of different bacterial species causing BSI between 2008 and 2016 as opposed to the increase for each pathogen. Reporting pathogen increase could simply be related to an overall increase in BSI incidence, whereas reporting proportions of aetiological agents could give an indication of changes in the most prevalent species/pathogenicity etc.

Table 3 -- Why are there two measures of age? Why is comorbidity measured in three separate ways (individual conditions, number of comorbidities and CCI)? How do the authors know that the individual comorbidities were not the cause of death?

Table 4 -- Why was number of comorbidities chosen to be part of the adjusted model instead of CCI? CCI showed a significant relationship with the outcome in the univariate analysis and I would argue is a superior measure of overall illness and frailty as it applies different weightings of severity to different conditions to compile an overall composite measure of multi-comorbidity.

Lines 359-361 -- Is the proportion of patients with multiple comorbidities increasing over time after adjusting for changes in demographics (age) or is this simply due to an aging population? Perhaps worth discussing a bit more.

Lines 361-362 -- Are "modern guidelines" truly recommending "higher and more frequent doses of antibiotics" in Sweden? This is in contradiction with most prescribing guidelines in other high-income settings as antibiotics are recommended for fewer conditions, delayed antibiotic prescribing or "wait and see" approaches are more frequently advised and shorter antibiotic durations are more frequently recommended as first line treatment.

Line 375 -- Could the authors please provide a bit more context around the "restricted use of systemic antibiotics" in Sweden? What kinds of policies have been implemented to achieve this?

Lines 382-388 -- As this is quite a surprising result which is not in line with previous comparable studies, I believe this requires more discussion as to why this particular patient group (younger, less ill patients) had a higher rate of MDR infections, leading to the effect on morbidity. Could there be factors related to travel? Better antibiotic stewardship in long-term care facilities and primary care making the elderly less likely to receive antibiotics (although this seems unlikely, but perhaps possible in Sweden)? More discussion around possible contributing factors would be welcome.

Lines 404-406 -- This is indeed a major limitation, the possible implications of which should be discussed and explored further.

Smaller amendments:

Line 78 -- Define BSI in the first instance

Line 84 -- "...has not increased significantly in the last..."

Line 86 -- Is this increase in Sweden in 2017?

Line 88 -- Please avoid the use of "probably"

Line 94 -- "Since antimicrobial-resistant organisms have become..."

Line 108 -- Other information systems such as? Please specify

Line 123 -- I would call this a retrospective cohort study -- while the authors do present descriptive statistics, a comparative approach is taken when modelling mortality outcomes.

Study design -- It would be helpful to include the patient characteristics defining the cohort (age, gender, any other inclusion criteria besides just the region and the clinical diagnosis)

Lines 192-193 -- It is unclear as to whether the systemic antibiotics analysed were both community and hospital or just hospital. Is it possible to differentiate this within the registry so as to accurately define the numerator? Was antibiotic consumption aggregated by the region -- please clarify?

Line 220 -- Please remove "approximately"

Lines 221-222 -- Why not report on the median age over all the years of the study?

Line 223 -- Please refer to Table S4 and include percentages in the table.

Line 243 -- Is this the overall proportion of hospital admissions due to any cause or just BSI?

Lines 244-247 -- This sentence seems to contradict itself, please clarify

Lines 254-255 -- This sentence seems to contradict the previous sentence (both reporting hospital prescribing of systemic antibiotics but with different rates), please clarify

Antimicrobial resistance -- It seems slightly sporadic which trends the authors chose to highlight - were they the largest changes, the most important drug-bug combinations clinically in the region etc.? Table S6 is unclear with respect to percentages and counts, please consider making this table easier to interpret

Lines 286-288 -- This breakdown for 30-mortality is slightly confusing, was ESBL-E not included in AMR BSI? Or was AMR BSI not including ESBL-E or MDR-E? If so, why?

Table 1 -- This table is cut off in my PDF and therefore cannot be properly interpreted

Table 2 -- This appears to be presenting baseline characteristics, not the results of univariate analyses, please amend

Line 318 -- Was age a year-on-year change? If so, I would suggest using a categorical variable for age instead in order to report a more meaningful increase in risk

Line 339 -- Only one factor is mentioned, are there others?

Line 401 -- "...association between antibiotic use and antibiotic-resistant infection at the patient-level..."
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